Figure 3.
Most relevant phenotypic features of BMMCs and blood CTMCs in patients diagnosed with MCAS and distinct diagnostic categories of mastocytosis. On the basis of their BMMC phenotype, patients were classified as having a normal or reactive (CD25–CD2–CD30−/+CD33+FcɛRI+/hi) phenotype, a mixed normal (CD25–) and aberrant (CD25+) mature (FcɛRI+/hi) phenotype, an aberrant (CD25+) phenotype, or an immature (FcɛRI–/low) and aberrant (CD25+) phenotype. (A) Distribution of BMMC phenotypes according to diagnosis. (B-G) Levels of expression of distinct phenotypic markers on blood CTMCs expressed as mean fluorescence intensity (MFI) values (arbitrary units scaled from 0 to 262 144) per diagnostic category of SM are shown.

Most relevant phenotypic features of BMMCs and blood CTMCs in patients diagnosed with MCAS and distinct diagnostic categories of mastocytosis. On the basis of their BMMC phenotype, patients were classified as having a normal or reactive (CD25–CD2–CD30−/+CD33+FcɛRI+/hi) phenotype, a mixed normal (CD25–) and aberrant (CD25+) mature (FcɛRI+/hi) phenotype, an aberrant (CD25+) phenotype, or an immature (FcɛRI–/low) and aberrant (CD25+) phenotype. (A) Distribution of BMMC phenotypes according to diagnosis. (B-G) Levels of expression of distinct phenotypic markers on blood CTMCs expressed as mean fluorescence intensity (MFI) values (arbitrary units scaled from 0 to 262 144) per diagnostic category of SM are shown.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal